These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 22378813

  • 1. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME.
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [Abstract] [Full Text] [Related]

  • 2. Selective use of vandetanib in the treatment of thyroid cancer.
    Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A.
    Drug Des Devel Ther; 2015 Apr; 9():3459-70. PubMed ID: 26170630
    [Abstract] [Full Text] [Related]

  • 3. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K, Komoda M, Tomomatsu J, Okamoto T, Horiuchi K, Tsuji A, Ito Y, Todo T, Rito K, Takahashi S.
    Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
    [Abstract] [Full Text] [Related]

  • 4. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F.
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [Abstract] [Full Text] [Related]

  • 5. Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
    Liu Y, Qi M, Hou S, Shao L, Zhang J, Li Y, Liu Q.
    Medicine (Baltimore); 2017 Oct; 96(43):e8345. PubMed ID: 29069010
    [Abstract] [Full Text] [Related]

  • 6. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ, Seib CD, Gosnell J.
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [Abstract] [Full Text] [Related]

  • 7. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C.
    J Clin Oncol; 2012 Apr 01; 30(10):1114-21. PubMed ID: 22370318
    [Abstract] [Full Text] [Related]

  • 8. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R.
    J Clin Endocrinol Metab; 2010 Jun 01; 95(6):2664-71. PubMed ID: 20371662
    [Abstract] [Full Text] [Related]

  • 9. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
    Ton GN, Banaszynski ME, Kolesar JM.
    Am J Health Syst Pharm; 2013 May 15; 70(10):849-55. PubMed ID: 23640345
    [Abstract] [Full Text] [Related]

  • 10. Vandetanib for the treatment of medullary thyroid cancer.
    Chau NG, Haddad RI.
    Clin Cancer Res; 2013 Feb 01; 19(3):524-9. PubMed ID: 23231950
    [Abstract] [Full Text] [Related]

  • 11. Vandetanib therapy in medullary thyroid cancer.
    Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D.
    Drugs Today (Barc); 2012 Nov 01; 48(11):723-33. PubMed ID: 23170308
    [Abstract] [Full Text] [Related]

  • 12. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M.
    J Clin Oncol; 2010 Feb 10; 28(5):767-72. PubMed ID: 20065189
    [Abstract] [Full Text] [Related]

  • 13. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD.
    J Clin Oncol; 2011 Mar 10; 29(8):1059-66. PubMed ID: 21282542
    [Abstract] [Full Text] [Related]

  • 14. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF, Adam P, Frank-Raue K, Raue F, Berg E, Hoster E, Allelein S, Schott M, Kroiss M, Spitzweg C.
    Thyroid; 2021 Mar 10; 31(3):459-469. PubMed ID: 32781914
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang X, Qin Y, Li H, Bai C, Zhu T, Xu J, Wu C, Wu M, Wang C, Song H, Wei L, He J.
    Asian Pac J Cancer Prev; 2011 Mar 10; 12(11):2857-63. PubMed ID: 22393954
    [Abstract] [Full Text] [Related]

  • 16. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
    Chougnet CN, Schlumberger M, Leboulleux S, Baudin E.
    Bull Cancer; 2014 Sep 10; 101(9):891-5. PubMed ID: 25296193
    [Abstract] [Full Text] [Related]

  • 17. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
    Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ.
    Lancet Oncol; 2012 Sep 10; 13(9):897-905. PubMed ID: 22898678
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH, Robinson BG, Learoyd DL.
    Expert Opin Drug Saf; 2016 Aug 10; 15(8):1107-13. PubMed ID: 27301016
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.